Paul Autenried - Bristol-Myers Squibb Senior Vice President - Enterprise Services, CIO

President

Mr. Paul von Autenried is Chief Information Officer, Senior Vice President of the Company. From 2011 to 2012 Senior Vice President and Chief Information Officer 2012 to 2016 Senior Vice President, Enterprise Services and Chief Information Officer 2016 to present Senior Vice President, Chief Information Officer. since 2016.
Age 56
Tenure 8 years
Phone212-546-4000
Webhttp://www.bms.com

Similar Executives

Showing other executives

PRESIDENT Age

Ruud DobberAstraZeneca PLC ADR
N/A
DavidAlexandre GrosSanofi ADR
42
Bahija JallalAstraZeneca PLC ADR
55
Claire ThomasGlaxoSmithKline PLC ADR
N/A
Pam ChengAstraZeneca PLC ADR
54
Shuji HandaDaiichi Sankyo
N/A
Hiroyuki OkuzawaDaiichi Sankyo
61
Katarina AgeborgAstraZeneca PLC ADR
N/A
Dominique CarougeSanofi ADR
N/A
MarieFrance TschudinNovartis AG ADR
53
Stefan OelrichSanofi ADR
49
Andre WyssNovartis AG ADR
50
James BradnerNovartis AG ADR
49
William SiboldSanofi ADR
51
Shah HussainGlaxoSmithKline PLC ADR
48
Yoshitsugu ShitakaAstellas Pharma
N/A
Susanne SchaffertNovartis AG ADR
54
Jennifer BrendeltoBayer Aktiengesellschaft
N/A
Shreeram MDNovartis AG ADR
61
Olivier CharmeilSanofi ADR
55
JeanBaptiste ChatillonSanofi ADR
59
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people. Bristol Myers Squibb [BMYMP] is a Pink Sheet which is traded between brokers over the counter.

Bristol Myers Squibb Leadership Team

Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Bristol-Myers Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol-Myers Squibb in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol-Myers Squibb's short interest history, or implied volatility extrapolated from Bristol-Myers Squibb options trading.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in Bristol-Myers Pink Sheet

If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account